Literature DB >> 21085758

Endoscopic left sympathetic blockade in the treatment for dilated cardiomyopathy.

Paulo M Pêgo-Fernandes1, Luiz Felipe P Moreira, Germano Emílio C Souza, Fernando Bacal, Edimar Alcides Bocchi, Noedir Antônio G Stolf, Fábio Biscegli Jatene.   

Abstract

BACKGROUND: The level of sympathetic nervous activity is a major determinant of prognosis in patients with heart failure.
OBJECTIVE: The purpose of this investigation was to perform a proof-of-principle trial of therapeutic endoscopic left thoracic sympathetic blockade in heart failure patients to assess safety and immediate effects.
METHODS: Fifteen patients with dilated cardiomyopathy and left ventricular ejection fraction (LVEF) < 40%, New York Heart Association functional class II or III, and heart rate > 65 bpm, despite either adequate betablocker use or intolerant to it, were enrolled. Ten patients underwent left infra-stellate ganglion plus T3-T4 interspinal space clipping through videothoracoscopy, while the other five patients were randomized to a control group.
RESULTS: None of the treated patients had any procedure-related adverse cardiovascular events at the perioperative period. Two patients from the surgical group died due to pulmonary thromboembolism or myocardial infarction within 6 months of the initial follow-up, while three patients from the control group had heart failure progression and died or developed cardiogenic shock during the same period. Treated patients presented improvement in quality of life, level of physical activity and LVEF (from 25 ± 9% to 32 ± 8%, p=0.024) at 6 months of follow-up, whereas these parameters did not change in control patients.
CONCLUSION: Endoscopic left thoracic sympathetic blockade is feasible and appears to be safe in severe heart failure patients. This initial study suggests that this procedure might be an effective alternative approach to sympathetic blockade in the treatment of dilated cardiomyopathies.

Entities:  

Mesh:

Year:  2010        PMID: 21085758     DOI: 10.1590/s0066-782x2010005000152

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


  5 in total

Review 1.  Thoracic sympathectomy: a review of current indications.

Authors:  Moshe Hashmonai; Alan E P Cameron; Peter B Licht; Chris Hensman; Christoph H Schick
Journal:  Surg Endosc       Date:  2015-06-27       Impact factor: 4.584

2.  Inflammation, oxidative stress, and glial cell activation characterize stellate ganglia from humans with electrical storm.

Authors:  Olujimi A Ajijola; Donald B Hoover; Thomas M Simerly; T Christopher Brown; Jane Yanagawa; Reshma M Biniwale; Jay M Lee; Ali Sadeghi; Negar Khanlou; Jeffrey L Ardell; Kalyanam Shivkumar
Journal:  JCI Insight       Date:  2017-09-21

3.  Perspectives of bilateral thoracic sympathectomy for treatment of heart failure.

Authors:  Raphael Dos Santos Coutinho E Silva; Fernando Luiz Zanoni; Rafael Simas; Luiz Felipe Pinho Moreira
Journal:  Clinics (Sao Paulo)       Date:  2021-08-04       Impact factor: 2.365

4.  Increased ischemia-modified albumin and malondialdehyde levels in videothoracoscopic surgery.

Authors:  Mufide Oncel; Aysel Kiyici; Murat Oncel; Guven Sadi Sunam; Emel Sahin; Bahattin Adam
Journal:  Ann Thorac Med       Date:  2016 Jan-Mar       Impact factor: 2.219

5.  Surgical Sympathectomy: Can it be useful in cardiology?

Authors:  Paulo Manuel Pêgo-Fernandes
Journal:  Clinics (Sao Paulo)       Date:  2020-04-06       Impact factor: 2.365

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.